Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vext Science's Revenue for the
three
months ended in Mar. 2026 was €10.52 Mil. Vext Science's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.64 Mil.
Hence, Vext Science's Receivables Turnover for the
three
months ended in Mar. 2026 was 16.38.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Vext Science Receivables Turnover Related Terms
Vext Science Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Vext Science's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Vext Science's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (FRA:VV5) has a Receivables Turnover of 16.38 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vext Science and its competitors. According to the industry distribution chart, Vext Science ranks #17 out of 951 companies in the Drug Manufacturers industry, placing it in the top 1.8%.
Is Vext Science's Receivables Turnover too high?
Vext Science's current Receivables Turnover is 16.38. The Drug Manufacturers industry median Receivables Turnover is 5.07. Vext Science's value of 16.38 is 223.1% above this industry median. Based on the distribution chart, Vext Science ranks #17 out of 951 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vext Science has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #17 out of 951 companies for Receivables Turnover. This places Vext Science in the top 2% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Vext Science's value of 16.38 is 223.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current Receivables Turnover of 16.38 is 223.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current Receivables Turnover is 16.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current Receivables Turnover of 16.38. The stock's GF Value™ is €0.94, compared to a current price of €0.15 — trading 84.3% below its estimated fair value. The current Receivables Turnover is 16.38 and 223.1% above the Drug Manufacturers industry median of 5.07. Vext Science's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current Receivables Turnover is 16.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.15 is trading 84.3% below its estimated GF Value™ of €0.94.
Key valuation signals for FRA:VV5:
Receivables Turnover: 16.38
GF Value™: €0.94 vs. price of €0.15 (84.3% below fair value)
Industry Position: 223.1% above the Drug Manufacturers median (#17 of 951)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
55GF Score
Get the complete analysis for FRA:VV5
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
